Matches 51 - 59 out of 59 < 1 2


Match Document Document Title Score
6284804 Topical suspension formulations containing ciprofloxacin and dexamethasone  
Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically...
666
7001615 Sustained release ophthalmic, otic and nasal suspension  
Sustained release suspension formulations for ophthalmic, otic and nasal administration are disclosed. The formulations comprise a basic active, a cation exchange resin, and a combination of a...
656
7402609 Olopatadine formulations for topical administration  
Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of...
646
9533053 High concentration olopatadine ophthalmic composition  
The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high...
628
6359016 Topical suspension formulations containing ciprofloxacin and dexamethasone  
Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically...
626
EP1115406A4 SUSTAINED RELEASE, AND COMFORTABLE OPHTHALMIC COMPOSITION AND METHOD FOR OCULAR THERAPY  
Abstract not available for EP1115406 Abstract of corresponding document: WO0018316 Disclosed are reduced stinging, sustained release ophthalmic formulations. Also disclosed are methods of...
619
EP2977042B1 OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION   596
EP2977042A1 OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION  
Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6 % (w/v) of olopatadine.
596
EP2114367B1 OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION   582

Search
Matches 51 - 59 out of 59 < 1 2
« search again